Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1993 Dec;37(12):2650–2655. doi: 10.1128/aac.37.12.2650

Pharmacokinetics and ex vivo susceptibility of cefpodoxime proxetil in patients receiving continuous ambulatory peritoneal dialysis.

C A Johnson 1, A Ateshkadi 1, S W Zimmerman 1, G S Hughes 1, W A Craig 1, P M Carey 1, M T Borin 1
PMCID: PMC192767  PMID: 8109931

Abstract

Pharmacokinetics of cefpodoxime, an extended-spectrum cephalosporin, were determined for eight noninfected patients on continuous ambulatory peritoneal dialysis (CAPD) and eight healthy volunteers. Subjects were matched for sex, age (+/- 6 years), and body weight (+/- 10 kg, except for one pair) and received a single 200-mg (cefpodoxime equivalents) oral dose of the prodrug cefpodoxime proxetil in an open-label, paired-design fashion. Dialysate (CAPD group only), plasma, and urine samples were collected and assayed for cefpodoxime by a microbiologic method. In addition, mean bactericidal titers of the effluent dialysate against selected bacterial strains often associated with CAPD-related peritonitis were determined at 6 and 24 h after the dose. There was a significant difference (P < 0.05) in all pharmacokinetic parameters between healthy and CAPD subjects, except for lag time to absorption. The mean peak plasma cefpodoxime concentration of 1.88 +/- 0.6 micrograms/ml occurred at 2.44 +/- 0.5 h for healthy volunteers, while the peak concentration of 3.25 +/- 1.4 micrograms/ml occurred at 12.0 +/- 4.2 h for patients on CAPD. The average elimination half-life in CAPD patients was approximately 12 times greater than that seen in healthy volunteers. Peritoneal dialysis had a minimal effect on cefpodoxime clearance. In healthy volunteers, 24.2% +/- 13% of the dose was recovered from the urine, in contrast to only 5.59% +/- 6.9% for CAPD patients. The mean bactericidal titers for all CAPD patients, at 6 and 24 h, were mostly less than 1:2 and did not exceed 1:4 for any of the isolates. Because of the decreased renal clearance and negligible dialysate clearance of cefpodoxime, and delayed drug absorption, the dosage interval for cefpodoxime proxetil may need to be extended in CAPD patients.

Full text

PDF
2650

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Blackwell B. G., Leggett J. E., Johnson C. A., Zimmerman S. W., Craig W. A. Ampicillin and sulbactam pharmacokinetics and pharmacodynamics in continuous ambulatory peritoneal dialysis (CAPD). Perit Dial Int. 1990;10(3):221–226. [PubMed] [Google Scholar]
  2. Borin M. T. A review of the pharmacokinetics of cefpodoxime proxetil. Drugs. 1991;42 (Suppl 3):13–21. doi: 10.2165/00003495-199100423-00005. [DOI] [PubMed] [Google Scholar]
  3. Borin M. T., Hughes G. S., Kelloway J. S., Shapiro B. E., Halstenson C. E. Disposition of cefpodoxime proxetil in hemodialysis patients. J Clin Pharmacol. 1992 Nov;32(11):1038–1044. doi: 10.1002/j.1552-4604.1992.tb03808.x. [DOI] [PubMed] [Google Scholar]
  4. Borin M. T., Hughes G. S., Patel R. K., Royer M. E., Cathcart K. S. Pharmacokinetic and tolerance studies of cefpodoxime after single- and multiple-dose oral administration of cefpodoxime proxetil. J Clin Pharmacol. 1991 Dec;31(12):1137–1145. doi: 10.1002/j.1552-4604.1991.tb03686.x. [DOI] [PubMed] [Google Scholar]
  5. Brown-Cartwright D., Smith H. J., Feldman M. Gastric emptying of an indigestible solid in patients with end-stage renal disease on continuous ambulatory peritoneal dialysis. Gastroenterology. 1988 Jul;95(1):49–51. doi: 10.1016/0016-5085(88)90289-2. [DOI] [PubMed] [Google Scholar]
  6. Fass R. J., Helsel V. L. In vitro activity of U-76,252 (CS-807), a new oral cephalosporin. Antimicrob Agents Chemother. 1988 Jul;32(7):1082–1085. doi: 10.1128/aac.32.7.1082. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Hughes G. S., Heald D. L., Barker K. B., Patel R. K., Spillers C. R., Watts K. C., Batts D. H., Euler A. R. The effects of gastric pH and food on the pharmacokinetics of a new oral cephalosporin, cefpodoxime proxetil. Clin Pharmacol Ther. 1989 Dec;46(6):674–685. doi: 10.1038/clpt.1989.204. [DOI] [PubMed] [Google Scholar]
  8. Hughes G. S., Jr, Heald D. L., Patel R., Spillers C. R., Batts D. H., Euler A. R. Gastric emptying and the pharmacokinetics of the cephalosporin antibiotic, cefpodoxime proxetil. Methods Find Exp Clin Pharmacol. 1990 Apr;12(3):197–204. [PubMed] [Google Scholar]
  9. Höffler D., Koeppe P., Corcilius M., Przyklinik A. Cefpodoxime proxetil in patients with endstage renal failure on hemodialysis. Infection. 1990 May-Jun;18(3):157–162. doi: 10.1007/BF01642104. [DOI] [PubMed] [Google Scholar]
  10. Jones R. N., Barry A. L. Antimicrobial activity and disk diffusion susceptibility testing of U-76,253A (R-3746), the active metabolite of the new cephalosporin ester, U-76,252 (CS-807). Antimicrob Agents Chemother. 1988 Apr;32(4):443–449. doi: 10.1128/aac.32.4.443. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Jones R. N., Barry A. L., Pfaller M., Allen S. D., Ayers L. W., Fuchs P. C. Antimicrobial activity of U-76,252 (CS-807), a new orally administered cephalosporin ester, including recommendations for MIC quality control. Diagn Microbiol Infect Dis. 1988 Jan;9(1):59–63. doi: 10.1016/0732-8893(88)90063-6. [DOI] [PubMed] [Google Scholar]
  12. Minami H., McCallum R. W. The physiology and pathophysiology of gastric emptying in humans. Gastroenterology. 1984 Jun;86(6):1592–1610. [PubMed] [Google Scholar]
  13. St Peter J. V., Borin M. T., Hughes G. S., Kelloway J. S., Shapiro B. E., Halstenson C. E. Disposition of cefpodoxime proxetil in healthy volunteers and patients with impaired renal function. Antimicrob Agents Chemother. 1992 Jan;36(1):126–131. doi: 10.1128/aac.36.1.126. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Tremblay D., Dupront A., Ho C., Coussediere D., Lenfant B. Pharmacokinetics of cefpodoxime in young and elderly volunteers after single doses. J Antimicrob Chemother. 1990 Dec;26 (Suppl E):21–28. doi: 10.1093/jac/26.suppl_e.21. [DOI] [PubMed] [Google Scholar]
  15. Utsui Y., Inoue M., Mitsuhashi S. In vitro and in vivo antibacterial activities of CS-807, a new oral cephalosporin. Antimicrob Agents Chemother. 1987 Jul;31(7):1085–1092. doi: 10.1128/aac.31.7.1085. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Wright R. A., Clemente R., Wathen R. Gastric emptying in patients with chronic renal failure receiving hemodialysis. Arch Intern Med. 1984 Mar;144(3):495–496. [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES